Title : Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provinces.

Pub. Date : 2018 Oct

PMID : 29688882






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 RESULTS: Both androgen receptor-axis-targeted therapies (ARATs), abiraterone acetate plus prednisone and enzalutamide, are funded by provinces in the pre-and post-chemotherapy setting, however, sequential ARAT use is not funded. Abiraterone Acetate androgen receptor Homo sapiens